Evidence map›Paper›PMID 33374729›Full record

ArticlePharmaceutics2020

Effect of Diphenyleneiodonium Chloride on Intracellular Reactive Oxygen Species Metabolism with Emphasis on NADPH Oxidase and Mitochondria in Two Therapeutically Relevant Human Cell Types.

Sergejs Zavadskis, Adelheid Weidinger, Dominik Hanetseder, Asmita Banerjee, Cornelia Schneider, Susanne Wolbank, Darja Marolt Presen, Andrey V Kozlov

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Oxphos targeting ofFrontiers in oncology · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Sergejs ZavadskisLudwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Trauma Research Center, Austrian Cluster for Tissue Regeneration, A-1200 Vienna, Austria.ORCID 0000-0002-3443-4259
Adelheid WeidingerLudwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Trauma Research Center, Austrian Cluster for Tissue Regeneration, A-1200 Vienna, Austria.ORCID 0000-0002-2759-211X
Dominik HanetsederLudwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Trauma Research Center, Austrian Cluster for Tissue Regeneration, A-1200 Vienna, Austria.ORCID 0000-0003-2625-3842
Asmita BanerjeeLudwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Trauma Research Center, Austrian Cluster for Tissue Regeneration, A-1200 Vienna, Austria.ORCID 0000-0002-0356-9513
Cornelia SchneiderLudwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Trauma Research Center, Austrian Cluster for Tissue Regeneration, A-1200 Vienna, Austria.ORCID 0000-0002-9899-049X
Susanne WolbankLudwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Trauma Research Center, Austrian Cluster for Tissue Regeneration, A-1200 Vienna, Austria.
Darja Marolt PresenLudwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Trauma Research Center, Austrian Cluster for Tissue Regeneration, A-1200 Vienna, Austria.
Andrey V KozlovLudwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Trauma Research Center, Austrian Cluster for Tissue Regeneration, A-1200 Vienna, Austria.ORCID 0000-0002-0834-4997
Ludwig Boltzmann Institute for Traumatology, The Research Center in Cooperation with AUVA · ATSechenov University · RU

Funding

Horizon 2020 Research and Innovation Program 657716The Austrian Research Promotion Agency (FFG) 854180The Austrian Research Promotion Agency (FFG) 867803
6 · The paper itself

Abstract

Reactive oxygen species (ROS) have recently been recognized as important signal transducers, particularly regulating proliferation and differentiation of cells. Diphenyleneiodonium (DPI) is known as an inhibitor of the nicotinamide adenine dinucleotide phosphate oxidase (NOX) and is also affecting mitochondrial function. The aim of this study was to investigate the effect of DPI on ROS metabolism and mitochondrial function in human amniotic membrane mesenchymal stromal cells (hAMSCs), human bone marrow mesenchymal stromal cells (hBMSCs), hBMSCs induced into osteoblast-like cells, and osteosarcoma cell line MG-63. Our data suggested a combination of a membrane potential sensitive fluorescent dye, tetramethylrhodamine methyl ester (TMRM), and a ROS-sensitive dye, CM-H2DCFDA, combined with a pretreatment with mitochondria-targeted ROS scavenger MitoTEMPO as a good tool to examine effects of DPI. We observed critical differences in ROS metabolism between hAMSCs, hBMSCs, osteoblast-like cells, and MG-63 cells, which were linked to energy metabolism. In cell types using predominantly glycolysis as the energy source, such as hAMSCs, DPI predominantly interacted with NOX, and it was not toxic for the cells. In hBMSCs, the ROS turnover was influenced by NOX activity rather than by the mitochondria. In cells with aerobic metabolism, such as MG 63, the mitochondria became an additional target for DPI, and these cells were prone to the toxic effects of DPI. In summary, our data suggest that undifferentiated cells rather than differentiated parenchymal cells should be considered as potential targets for DPI.

Indexed as

differentiationdiphenyleneiodoniummitochondriaNADPH-oxidaseproliferationreactive oxygen species

Identifiers

PMID33374729
PMCPMC7823933
OpenAlexW3115139537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.